Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01798004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01798004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2013
Completion date
June 30, 2024
Enrollment
150 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

ganglioneuroblastoma, stage 1 neuroblastoma, stage 2 neuroblastoma, stage 2a neuroblastoma, stage 2b neuroblastoma, stage 3 neuroblastoma, stage 4 neuroblastoma, stage 4s neuroblastoma